ARTICLE | Clinical News
CDX-1307: Phase II started
May 24, 2010 7:00 AM UTC
Celldex began a U.S. Phase II trial in about 60 patients with newly diagnosed hCG-beta expressing muscle-invasive bladder cancer. Patients will receive neoadjuvant therapy with CDX-1307 plus cisplatin...